

25 January 2022

## **Subject: New Biologic Medications in Gastroenterology**

I am analysing the usage of new biologic medications in gastroenterology. I would greatly appreciate if you could answer the following two questions.

### **Question 1:**

Q1. How many patients were treated in November 2021 (or latest available month) by the gastroenterology department with the following drugs:

· Adalimumab (any brand or biosimilar)	410
· Infliximab (any brand or biosimilar)	340
· Ustekinumab (Stelara)	112
· Vedolizumab (Entyvio)	230
· Tofacitinib (Xeljanz)	3
· Filgotinib (Jyseleca)	0

### **Question 2:**

Q2. How many patients were treated in November 2021 (or latest available month) for Crohn's Disease ONLY with the following drugs:

· Adalimumab (any brand or biosimilar)	290
· Infliximab (any brand or biosimilar)	240
· Ustekinumab (Stelara)	110
· Vedolizumab (Entyvio)	90